Source: International Congress 2019 – Lung cancer?
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Taeyun Kim (Busan, South Korea). A case of pulmonary tuberculosis development after receiving immune check point inhibitor in an advanced non-small cell lung cancer. International Congress 2019 – Lung cancer?

Member's Comments

No comment yet.

Related content which might interest you: Does the lung function affect the survival time in patients with resected non-small cell lung cancer? Source: Annual Congress 2007 - Lung function parameters before and after thoracic surgery Year: 2007 The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007 Possibility of the specific efficacy of gefitinib for miliary lung metastasis in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004 Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer Source: Eur Respir Rev, 28 (153) 190058; 10.1183/16000617.0058-2019 Year: 2019 Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Does the incorporation of new generation cytotoxic agent improve the overall outcome in inoperable nonsmall cell lung cancer (NSCLC)? Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003 Does long treatment delay affect survival in metastatic non-small cell lung cancer Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 Should there be a specific management for large cell neuroendocrine carcinoma? Source: Annual Congress 2005 - Neuroendocrine tumours of the lung Year: 2005 The treatment of stage IV non-small cell lung cancer with target therapies Source: Annual Congress 2013 –Which treatment other than chemotherapy for stage IV NSCLC? Year: 2013 Do cavitating non-small cell lung cancer patients have a more aggressive disease? Source: Eur Respir J 2006; 28: Suppl. 50, 84s Year: 2006 A study on chemotherapy induced interstitial lung disease in patients with unresectable non-small cell lung cancer complicated by combined pulmonary fibrosis and emphysema Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 A modified ILD-GAP index for patients with non-small cell lung cancer and interstitial lung disease Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 A novel biologic classification of non-small cell lung cancer Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005 Our experience with crizotinib in the treatment of non-small cell lung cancer Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 The role of palliative radiotherapy in locally advanced non small cell lung cancer Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 A non-small cell lung cancer modelling by endogenous κ-ras manipulation Source: Annual Congress 2005 - Pathophysiology of lung cancer progression: impact in diagnosis and early detection Year: 2005 The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Efficacy of a pulmonary rehabilitation programme (PRP) after lung resection (LR) for cancer Source: Annual Congress 2005 - Pulmonary rehabilitation: an evidence-based intervention Year: 2005 Efficacy of local therapy for oligoprogressive disease after PD-1 blockade in advanced non-small cell lung cancer Source: Virtual Congress 2021 – COVID-19 and management of lung cancer Year: 2021